| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.3 |